Next Phase Newsletter

A venture capital firm based in Southern California is actively making early-stage investments in all sectors of healthcare. The firm is currently investing from their first fund, through which the firm will invest in 25-40 companies over the next 3-5 years. To date, the firm’s current portfolio includes over 25 companies. The firm’s typical size of initial investment is $100-500K in the form of equity, convertible note, among other monetary vehicles. The firm focuses on Seed to Series A-stage companies that are based in Southern California, but opportunistically invest across all of USA and the world.

The firm invests in medical device, diagnostics, and digital health companies, but will generally not invest in therapeutics or biopharmaceuticals. The firm is opportunistic and will consider all promising technologies within the aforementioned sectors.

The firm generally invests in companies with a pre-money valuation less than $10M, but is capable of participating in investments in larger companies. The firm likes to companies within 6 months of FDA clearance or approval, or revenue generation. The firm is open to working with small/inexperienced management teams and is agnostic with regards to management team requirements. The firm is an active investor who selectively serve on boards, and actively engages their LPs who have healthcare subject matter expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The company is Canada’s largest diagnostic lab and is the leading diagnostic testing facility for communities in Ontario and BC. The company does 120 million diagnostic tests a year in centralized labs and 450+ offices and patient service centers. The firm has made a number of acquisitions in the last 10 years, and consolidated lab testing by acquiring the largest competitive lab in Ontario and the only competitive lab in BC. The firm is looking solely for long term strategic partnerships with organizations that have technology in point of care testing and novel diagnostic testing as well as technology platforms. The company looks globally for opportunities.

The company is looking for strategic partnerships in both the medical device and diagnostic sectors. The firms main focus is point of care technologies, rapid testing, cardiovascular, wearables and biometrics, and the firm is open to all indications. The company also looks to women and men’s health, as well as novel mental health and brain related technologies. The firm is open to pre-clinical companies.

The company looks for management teams with deep subject matter expertise within their field and a strong track record. The firm is open to both co-investing or leading an investment, where they will seek board seat representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is Healthcare focused fund, headquartered in Shanghai and has presence in US and Europe. The fund has strong preference for early stage opportunities. The senior team members have strong operating experience in biotech and pharma companies, they have strong preference to lead investments and play active contribute to the success in their portfolio companies.

The firm is particularly keen on cardiovascular, regenerative medicine, CNS and hearing related opportunities. Panacea Venture is otherwise agnostic in regards to specific disease indications and is willing to look at all early-stage opportunities, however, diagnostics is currently considered as a low priority.

As the firm seeks to be an active lead investor, the firm strongly prefers a board seat in companies. Outside of the board requirement, the firm is looking for strong management team with passion and capability in advancing the company’s technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture builder founded in 2016 and is headquartered in the United Kingdom. The firm seeks to build new ventures from scratch, generating innovation in novel science and technology from the earliest stages of development. Currently, the firm is focused on 4 main pillars: energy, agriculture, curative therapeutics, and computation. The firm invests pre-seed/seed capital into the companies they build. The firm will consider global opportunities.

Within life sciences, the firm is indication agnostic and has worked in areas including cystic fibrosis, oncology, neurodegeneration and microbiome. The firm has partnered with groups such as the Cystic Fibrosis Foundation and Cancer Research UK to devise new therapeutic approaches in their key focus areas. The firm has a strong interest in cell & gene therapy and synthetic biology, but is open to considering all other modalities – the firm has also launched companies that work on a more traditional approach. In terms of stage of development, the firm invests in the companies it builds at formation stage and is open to working together with other organizations to undertake company creation and support proof-of-concept data generation. The firm generally does not currently build, or invest in, medical devices, diagnostics, or digital health companies.

As a venture builder, the firm does not have strict requirements or expectations on company operations or management team. The firm has generally built companies in the UK. That said, the firm has worked with scientists all across the globe to build its companies, and their portfolio also includes companies in other geographies such as the USA.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A healthcare and life sciences branch of a leading manufacturing company invests primarily in Series A or later companies in digital health, medical devices, genomics and molecular diagnostics technologies, but can expand their focus conditionally. While some of their investments are strategic, the firm is willing to invest outside of corporate strategic areas. The firm is a global investor, and can act as both a strategic partner and a financial investor, depending on the company.

The firm can invest as a strategic manufacturing company, but is also interested in software-enabled technologies and connected devices. While the firm may consider PMA devices, most investments are in 510k-pathway products. For purely digital health products, such as IoT technology, the firm would like to see some revenue and market traction before investing. For both medical devices and digital health, the firm is agnostic to indication. The firm’s interest in genomics and molecular diagnostics primarily relate to the oncology space, and prefer to see technologies with some clinical data.

The firm may take a board seat after investing, if they are the lead or if they have strategic value to offer the portfolio company, but will generally not take a board seat if they are co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical that has primarily focused on reproductive and maternal health is now looking to expand into other indications. Additionally, the firm is interested in AI drug development platforms. The firm is willing to partner with early to late stage companies, and will partner globally.

The firm is interested in therapeutics in the areas of reproductive and maternal health, and is interested in expanding into the area of GI, such as therapeutics treating IBD and UC, and is interested in the microbiome as well. The firm is interested in all modalities. In addition to therapeutics, the firm is also interested in AI platforms for drug discovery and biomarker identification.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture firm located in the USA has 4 area of focus: fintech, digital health, data analytics and insurtech. The firm has made 36 investments total and the average check size is around $1M in Seed or Series A rounds. The firm’s capital structure is typically SAFEs and priced rounds. The firm also has a second venture fund of $5M for Pre-seed and Seed rounds, and this fund is exclusively for companies located in their state. The firm invests across the US and Canada.

The firm’s main areas of focus are fintech, digital health, data analytics and insurtech. Since the firm is a branch of a legacy life insurance company, within the insurtech and fintech sectors, the firm focuses on the evolution of the consumer wallet and how they can develop new products in partnership with startups. Within the digital health sector, the firm focuses on data collection and items that can influence their underwriting models, electronic med records, wearables, remote monitoring devices, and the firm is looking more into implantables in the future. The firm isn’t interested in physician scaling tools, or any companies focused solely on hardware. The firm is open to pre-prototype companies.

The firm looks for diverse management teams, with 2 or 3 founders. The firm likes to see subject matter expertise, traction in product development or alpha/beta testing, and repeat founders are a plus, but not required. The firm also looks for a strong advisor team. The firm typically co-invests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.